PCA
FENC icon

Prospect Capital Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Prospect Capital Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.35M Buy
+497,800
New +$4.06M 2.43% 18

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prospect Capital Advisors's FENC Position: Q2 2026 in Review

Prospect Capital Advisors opened a new position in Fennec Pharmaceuticals (FENC) in Q2 2026: 497,800 shares worth $5.35M. The stake represents 2.43% of the portfolio and ranks #18 among its holdings.

98 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Prospect Capital Advisors held 497,800 shares of Fennec Pharmaceuticals worth $5.35M as of Q2 2026.
  • Fennec Pharmaceuticals was a new Prospect Capital Advisors position in Q2 2026.
  • Fennec Pharmaceuticals made up 2.43% of Prospect Capital Advisors's portfolio in Q2 2026, its #18 holding.
  • 98 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Prospect Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.